Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes

Citation
M. Fresta et G. Puglisi, Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes, PHARM RES, 16(12), 1999, pp. 1843-1849
Citations number
41
Categorie Soggetti
Pharmacology & Toxicology
Journal title
PHARMACEUTICAL RESEARCH
ISSN journal
07248741 → ACNP
Volume
16
Issue
12
Year of publication
1999
Pages
1843 - 1849
Database
ISI
SICI code
0724-8741(199912)16:12<1843:ROMPIC>2.0.ZU;2-S
Abstract
Purpose. Cerebral ischemia represents a serious therapeutic challenge. we i nvestigated the therapeutic efficacy of CDP-choline-loaded liposomes agains t cerebral ischemia. The determination of post-ischemic brain recovery by E EG analysis was carried out to evaluate the effect of CDP-choline-loaded li posomes with respect to the free drug on the maturation of ischemic injury. Methods. Long-circulating unilamellar liposomes were prepared by a freeze a nd thaw procedure followed by an extrusion through polycarbonate membranes. Wistar rats were ischemized by bilateral clamping of the common carotid ar teries. Free or liposomally entrapped drug was administered (20 mg/kg) just after ischemia and thereafter once a day for six days. Post-ischemic survi val, neuronal membrane peroxidation and brain recovery (EEG analysis) were evaluated. Results. The post-ischemic reperfused rats treated with CDP-choline-loaded liposomes showed a higher survival rate than animals treated with the free drug. The delayed cerebral neurodegenerative injury due to an ischemic even t, referred to as maturation phenomenon, was substantially reduced with the administration of the liposomal formulation. The liposomal carrier showed a marked protection against lipoperoxidative damage. Conclusions. Liposomes ensured a rapid recovery of the damaged membranous s tructure of the neuronal cells, allowing a significant improvement of brain functionality. The reduction of the maturation phenomenon may probably be of particular importance in humans, where a fundamental problem is the qual ity of life after an ischemic event.